Mohamad Mohty

Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in Multiple Myeloma: 30 Years in the Making

Immunomodulatory drugs (IMiDs) have fundamentally reshaped multiple myeloma therapy, extending survival and establishing durable backbones across induction, relapse, and maintenance. Cereblon's identification as a druggable E3 ligase substrate receptor created the mechanistic pat...

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis

Abstract In previous analyses of MAIA, daratumumab plus lenalidomide/dexamethasone (D-Rd) significantly improved progression-free survival and overall survival (OS) versus lenalidomide/dexamethasone (Rd) in transplant-ineligible newly diagnosed multiple myeloma (NDMM). We report...